267 related articles for article (PubMed ID: 10501233)
1. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT).
Cheng E; Cárdenas-Freytag L; Clements JD
Vaccine; 1999 Aug; 18(1-2):38-49. PubMed ID: 10501233
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb.
Martin M; Metzger DJ; Michalek SM; Connell TD; Russell MW
Infect Immun; 2000 Jan; 68(1):281-7. PubMed ID: 10603399
[TBL] [Abstract][Full Text] [Related]
3. Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants.
McCluskie MJ; Weeratna RD; Clements JD; Davis HL
Vaccine; 2001 Jun; 19(27):3759-68. PubMed ID: 11395211
[TBL] [Abstract][Full Text] [Related]
4. Differential biological and adjuvant activities of cholera toxin and Escherichia coli heat-labile enterotoxin hybrids.
Bowman CC; Clements JD
Infect Immun; 2001 Mar; 69(3):1528-35. PubMed ID: 11179323
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the reactogenicity, adjuvanticity and antigenicity of LT(R192G) and LT(R192G/L211A) by intradermal immunization in mice.
Maciel M; Smith M; Poole ST; Laird RM; Rollenhagen JE; Kaminski RW; Wenzel H; Bourgeois AL; Savarino SJ
PLoS One; 2019; 14(11):e0224073. PubMed ID: 31682624
[TBL] [Abstract][Full Text] [Related]
6. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity.
Dickinson BL; Clements JD
Infect Immun; 1995 May; 63(5):1617-23. PubMed ID: 7729864
[TBL] [Abstract][Full Text] [Related]
7. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections.
Jakobsen H; Schulz D; Pizza M; Rappuoli R; Jónsdóttir I
Infect Immun; 1999 Nov; 67(11):5892-7. PubMed ID: 10531245
[TBL] [Abstract][Full Text] [Related]
8. Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses.
Tierney R; Beignon AS; Rappuoli R; Muller S; Sesardic D; Partidos CD
J Infect Dis; 2003 Sep; 188(5):753-8. PubMed ID: 12934192
[TBL] [Abstract][Full Text] [Related]
9. The mucosal adjuvanticity of two nontoxic mutants of Escherichia coli heat-labile enterotoxin varies with immunization routes.
Park EJ; Chang JH; Kim JS; Yum JS; Chung SI
Exp Mol Med; 2000 Jun; 32(2):72-8. PubMed ID: 10926118
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.
Norton EB; Lawson LB; Freytag LC; Clements JD
Clin Vaccine Immunol; 2011 Apr; 18(4):546-51. PubMed ID: 21288994
[TBL] [Abstract][Full Text] [Related]
11. Role of GM1 binding in the mucosal immunogenicity and adjuvant activity of the Escherichia coli heat-labile enterotoxin and its B subunit.
de Haan L; Verweij WR; Feil IK; Holtrop M; Hol WG; Agsteribbe E; Wilschut J
Immunology; 1998 Jul; 94(3):424-30. PubMed ID: 9767427
[TBL] [Abstract][Full Text] [Related]
12. Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine.
Lu X; Clements JD; Katz JM
Vaccine; 2002 Jan; 20(7-8):1019-29. PubMed ID: 11803061
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin.
Takahashi I; Marinaro M; Kiyono H; Jackson RJ; Nakagawa I; Fujihashi K; Hamada S; Clements JD; Bost KL; McGhee JR
J Infect Dis; 1996 Mar; 173(3):627-35. PubMed ID: 8627026
[TBL] [Abstract][Full Text] [Related]
14. Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants.
Nawar HF; Arce S; Russell MW; Connell TD
Infect Immun; 2007 Feb; 75(2):621-33. PubMed ID: 17118982
[TBL] [Abstract][Full Text] [Related]
15. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants.
Douce G; Giannelli V; Pizza M; Lewis D; Everest P; Rappuoli R; Dougan G
Infect Immun; 1999 Sep; 67(9):4400-6. PubMed ID: 10456880
[TBL] [Abstract][Full Text] [Related]
16. Rotavirus 2/6 virus-like particles administered intranasally in mice, with or without the mucosal adjuvants cholera toxin and Escherichia coli heat-labile toxin, induce a Th1/Th2-like immune response.
Fromantin C; Jamot B; Cohen J; Piroth L; Pothier P; Kohli E
J Virol; 2001 Nov; 75(22):11010-6. PubMed ID: 11602741
[TBL] [Abstract][Full Text] [Related]
17. Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit.
Boyaka PN; Ohmura M; Fujihashi K; Koga T; Yamamoto M; Kweon MN; Takeda Y; Jackson RJ; Kiyono H; Yuki Y; McGhee JR
J Immunol; 2003 Jan; 170(1):454-62. PubMed ID: 12496431
[TBL] [Abstract][Full Text] [Related]
18. Mucosal immunogenicity and adjuvant activity of the recombinant A subunit of the Escherichia coli heat-labile enterotoxin.
De Haan L; Holtrop M; Verweij WR; Agsteribbe E; Wilschut J
Immunology; 1999 Aug; 97(4):706-13. PubMed ID: 10457227
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant effect of non-toxic mutants of E. coli heat-labile enterotoxin following intranasal, oral and intravaginal immunization.
De Magistris MT; Pizza M; Douce G; Ghiara P; Dougan G; Rappuoli R
Dev Biol Stand; 1998; 92():123-6. PubMed ID: 9554265
[TBL] [Abstract][Full Text] [Related]
20. Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines.
Hartman AB; Van De Verg LL; Venkatesan MM
Infect Immun; 1999 Nov; 67(11):5841-7. PubMed ID: 10531238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
